Table 1

Selected baseline characteristics of the safety population

ParameterPsO cohort (n=5181)PsA cohort (n=1380)AS cohort (n=794)
Gender
 Female (n, %)1743 (33.6%)742 (53.8%)265 (33.4%)
 Male (n, %)3438 (66.4%)638 (46.2%)529 (66.6%)
Age, years, mean (SD)45.7 (13.3)48.8 (12.0)42.4 (12.3)
Prior exposure (with inadequate response) to TNF antagonists, n (%)NA*435 (31.5%)227 (28.6%)
Prior exposure (with inadequate response) to biological therapy, n (%)784 (15.1%)NANA
Current smoker at BL, n (%)1585 (30.6%)262 (19%)234 (30%)
Prior azathioprine use, n (%)7 (0.1%)15 (1.1%)1 (0.1%)
  • *Specific data on prior TNF antagonist exposure is not available for the PSO cohort however 784 (15.1%) of these patients had a previous exposure with inadequate response to biologic therapies including TNF antagonists.

  • AS, ankylosing spondylitis; BL, baseline; CD, Crohn’s disease; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.